

ASX Announcement

29 November 2022

Change of auditor

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, in compliance with ASX Listing Rule 3.16.3, advises the appointment of Stantons International Audit and Consulting Pty Ltd ("Stantons") as auditor of Regeneus.

The appointment follows a tender process and the review and receipt of a number of submissions. Stantons was selected on the basis of their reputation and experience, particularly with similar sized companies to Regeneus in the life sciences.

The appointment was made by Regeneus' members by ordinary resolution at today's Annual General Meeting.

The change follows the resignation of Regeneus' previous auditor, Grant Thornton, in accordance with Section 329(5) of the Corporations Act.

Regeneus would like to thank Grant Thornton for their past assistance and services as auditor over the last 11 years.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

Hannah Howlett, WE Communications
T: 04 5064 8064
E: hhowlett@we-worldwide.com